Skip to main content
main-content

Genitourinary cancers

Free registration

Medicine Matters is developed for healthcare professionals as

a premier resource for the latest clinical information in medicine.

medwireNews editor's pick

Multiparametric MRI does not render systematic prostate biopsy obsolete

Man in scanner

Pre-biopsy multiparametric magnetic resonance imaging improves the detection of clinically significant prostate cancer in biopsy-naive patients but does not appear to remove the need for systematic biopsy, MRI-FIRST study data show.

medwireNews editor's pick

Neoadjuvant pembrolizumab ‘worthwhile’ for some invasive bladder cancers

IV drip_patient's hand

Neoadjuvant pembrolizumab therapy results in an “impressively high” pathologic complete response rate among patients with programmed cell death ligand 1-positive muscle-invasive bladder carcinoma, researchers say.

medwireNews@ESMO2018

Genitourinary cancers coverage at the ESMO Congress 2018

Munich
Expert opinion

Bipolar androgen therapy: Progress and future directions

Bipolar androgen therapy: Progress and future directions

Michael Schweizer (University of Washington, Seattle, USA) outlines a new therapy that utilizes both androgen deprivation and administration, which may potentially have benefit for prostate cancer patients.

Expert opinion

Urinary biomarkers in the management of prostate cancer

Urinary biomarkers in the management of prostate cancer

Non-invasive biomarkers have the potential to guide and improve prostate cancer management in many ways. Maria Frantzi, Agnieszka Latosinska, and Harald Mischak (Mosaiques Diagnostics GmbH, Germany) outline some promising markers and what is needed to implement them in the clinic.

30-10-2018 | Castration-resistant prostate cancer | ESMO 2018 | Video

Abiraterone alone likely suppresses testosterone sufficiently in mCRPC patients

Carsten Ohlmann discusses findings of the phase II SPARE trial that investigated forgoing LHRH therapy in metastatic prostate cancer patients receiving abiraterone acetate (5:16).

30-10-2018 | Renal cell carcinoma | ESMO 2018 | Video

Expert comment on the JAVELIN Renal 101 trial

ESMO expert Markus Joerger gives his views on the JAVELIN Renal 101 study pitting the combination of avelumab and axitinib against sunitinib in the first-line advanced RCC setting (1:48).

03-06-2018 | Prostate cancer | ASCO 2018 | Video

Expert commentary: Unpicking the relationship between prostate cancer treatment efficacy, survival and race

ASCO Expert Robert Dreicer reviews two studies looking at differences in survival rates between Black and White men with metastatic castration-resistant prostate cancer (3:16). 

Read the accompanying news story here.

18-01-2019 | Renal cell carcinoma | News

Potential ‘risk of harm’ for older women with adjuvant sunitinib for RCC

Adjuvant treatment with sunitinib may be associated with an increased mortality risk for older female patients with renal cell carcinoma, suggests a post-hoc analysis of the ASSURE trial that compared sunitinib and sorafenib with placebo.

16-01-2019 | Castration-resistant prostate cancer | News

Germline BRCA2 mutations impact mCRPC survival

Germline mutations in the BRCA2 gene, but not other DNA damage repair genes, are associated with poorer outcomes among patients with metastatic castration-resistant prostate cancer, study findings indicate.

14-01-2019 | Bladder cancer | News

Smoking associated with unfavorable neoadjuvant therapy response in bladder cancer

Patients with muscle-invasive bladder cancer who are current or former smokers are more likely to respond poorly to cisplatin-based neoadjuvant chemotherapy than their nonsmoking counterparts, researchers report in BJU International.

Expert opinion

Bipolar androgen therapy: Progress and future directions

Bipolar androgen therapy: Progress and future directions

Michael Schweizer (University of Washington, Seattle, USA) outlines a new therapy that utilizes both androgen deprivation and administration, which may potentially have benefit for prostate cancer patients.

Journal articles and book chapters

21-08-2018 | Prostate cancer | Article

Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations

Crawford ED, Heidenreich A, Lawrentschuk N et al. Prostate Cancer Prostatic Dis 2018. doi:10.1038/s41391-018-0079-0.

29-06-2018 | Castration-resistant prostate cancer | Article

Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer

Hussain M et al. N Engl J Med 2018; 378(26): 2465-2474. doi:10.1056/NEJMoa1800536

28-06-2018 | PARP inhibitors | Article

Synthetic lethal therapies for cancer: what’s next after PARP inhibitors?

Ashworth A. Lord CJ. Nat Rev Clin Oncol 2018. doi:10.1038/s41571-018-0055-6

14-06-2018 | Renal cell carcinoma | Article

An interdisciplinary consensus on the management of bone metastases from renal cell carcinoma

Grünwald V et al. Nat Rev Urol 2018. doi:10.1038/s41585-018-0034-9.

05-06-2018 | Prostate cancer | Article

Statin use and time to progression in men on active surveillance for prostate cancer

Jayalath VH et al. Prostate Cancer Prostatic Dis 2018. doi:10.1038/s41391-018-0053-x

05-06-2018 | Radiotherapy | Article

Safety of combining radiotherapy with immune-checkpoint inhibition

Hwang WL et al. Nat Rev Clin Oncol 2018. doi: 10.1038/s41571-018-0046-7

04-06-2018 | Renal cell carcinoma | Article

Epigenetics in renal cell cancer: mechanisms and clinical applications

Joosten SC et al. Nat Rev Urol 2018. doi:10.1038/s41585-018-0023-z

Images and illustrations

12-04-2018 | Prostate cancer | Images and illustration slides | Collection

Prostate cancer imaging

This downloadable powerpoint slide set presents an overview of the imaging techniques used to assess prostate cancer from initial diagnosis and staging, to evaluation of residual or recurrent disease after treatment. These slides can be used for reference purposes or for inclusion in one’s own slide sets. Source: Vargas HA et al. Prostate Cancer Imaging. In: Bach Am, Zhang J, eds. Atlas of Genitourinary Oncological Imaging. Springer New York.

Our Editorial Board advisor

Axel S Merseburger MD

Dr Merseburger is currently Professor and Chairman of the Clinic of Urology at University Hospital Schleswig-Holstein in Lübeck, Germany, having previously served as Vice Chairman of the Department of Urologic Oncology and Director of the Urologic Oncology Programme at Hannover Medical School, Germany. Dr Merseburger’s key areas of interest are renal cell carcinoma, prostate cancer and transitional cell carcinoma, with special attention given to novel markers and prognostic factors. He is a principal investigator in German Phase II and III trials.

image credits